Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05914610 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 25, 2023 (before its estimated July 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 1, 2023 to Sep 1, 2023
    • Interventions: Envolimab (Drug), Fuquinitinib (Drug), Oxaliplatin (Drug), Tegafur (Drug) to Envolimab (Drug), Fruquintinib (Drug), Oxaliplatin (Drug), Tegafur (Drug)
    • Study title revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.
Trial Details
NCT Number NCT05914610
Lead Sponsor Fujian Medical University
Conditions
(from sponsor)		 Gastric Cancer
Related terms Stomach Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov